Skyclarys access in Saudi Arabia through the SFDA Personal Importation Program
How Saudi families with a genetically confirmed Friedreich's ataxia diagnosis source Skyclarys (omaveloxolone), the first disease-modifying therapy for FA, what the PIP application package looks like, and where Reserve Meds fits.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Skyclarys is the brand name for omaveloxolone, an oral once-daily small-molecule Nrf2 activator approved by the US FDA on 28 February 2023 for the treatment of Friedreich's ataxia (FA) in adults and adolescents aged 16 years and older. It is the first and remains the only disease-modifying therapy approved for Friedreich's ataxia. The European Medicines Agency granted centralised marketing authorisation on 9 February 2024 and the UK MHRA approved Skyclarys on 23 April 2025. The SFDA has not registered Skyclarys for local commercial sale in the Kingdom of Saudi Arabia as of this page date. A Saudi family with a genetically confirmed FA diagnosis can reach Skyclarys lawfully through the SFDA Personal Importation Program (PIP), prescribed by a SCFHS-licensed neurologist and dispensed by an SFDA-licensed hospital or specialty import pharmacy. Reserve Meds coordinates the US-side sourcing and the documentation kit your neurologist needs to file the PIP application. Reserved for you.
Why Saudi families need Skyclarys through the named-patient pathway
Friedreich's ataxia is ultra-rare, affecting approximately 1 in 50,000 people worldwide. National payers in non-approved jurisdictions have no incentive to expedite a local registration for a small patient pool, and individual ataxia clinics cannot generate the volume that attracts distributor interest. The structural access pattern in Saudi Arabia is the third of the three the country module describes: the drug is FDA-approved (and EMA-approved, and MHRA-approved) but the manufacturer Biogen has not sought SFDA registration. Saudi families with an FA-affected child often have a confirmed genetic diagnosis through KFSH&RC's medical genetics service or another tertiary genomics programme, with no locally registered disease-modifying option to offer.
Friedreich's ataxia is genetic, progressive, and was for decades untreatable. The arrival of the first disease-modifying therapy created a sharp uptick in family-driven cross-border demand globally. Patient advocacy networks (Friedreich's Ataxia Research Alliance, Ataxia UK) actively educate families about the drug's existence. Saudi Vision 2030's Health Sector Transformation Program names genomics and rare-disease care as priority verticals, and pediatric and adolescent FA cases are being identified earlier through expanded genetic confirmation capability. The PIP framework was designed for exactly this situation: an FDA-approved medicine, no clinically equivalent locally registered alternative (no other disease-modifying FA therapy exists), and a serious progressive condition where the treating physician documents why this specific drug is appropriate for this specific genetically confirmed patient.
The SFDA Personal Importation Program for Skyclarys
The Saudi pathway for a KSA-licensed neurologist to obtain Skyclarys is the SFDA Personal Importation Program. PIP allows a SCFHS-licensed physician to request the import of a specific medicine for a specific named patient when the medicine is approved by a recognised reference authority (the US FDA, the EMA, and the UK MHRA for Skyclarys) and a clinically equivalent locally registered alternative is not suitable. Applications are filed through the dispensing institution's import pharmacy and increasingly routed through the SFDA Ghad digital platform.
For Skyclarys specifically, the clinical-justification angle that anchors the application is GAA genetic confirmation. Skyclarys is approved only for Friedreich's ataxia, and FA is defined molecularly by biallelic GAA trinucleotide repeat expansion in intron 1 of the FXN gene (or one GAA expansion in trans with a pathogenic FXN point mutation). Clinical suspicion alone is not sufficient. The PIP application is strongest when the neurologist's letter sets out (1) the molecular genetic confirmation of FA with the reporting laboratory named (specifically the GAA expansion size or the compound heterozygous mutation profile), (2) the clinical phenotype including age at onset and disease trajectory using a validated scale such as mFARS (modified Friedreich Ataxia Rating Scale), (3) confirmed age 16 years or older (the FDA-label age threshold), (4) baseline hepatic function (ALT, AST, total bilirubin) and the planned monitoring schedule, (5) cardiac baseline (BNP, echocardiogram where indicated, given FA-associated cardiomyopathy risk), and (6) lipid baseline.
A complete PIP package typically includes:
- Clinical justification letter from the treating neurologist (FA diagnosis with GAA genetic confirmation, severity assessment via mFARS or equivalent, prior therapies, why Skyclarys, why a locally registered alternative is not suitable)
- Genetic test report attached as a supporting document, with the reporting laboratory named
- Treating neurologist SCFHS license verification (neurology, pediatric neurology, or movement disorders subspecialty)
- Patient identifier in SFDA-required format
- Product details: Skyclarys 50 mg oral capsules in bottle format, manufacturer Biogen (originally Reata Pharmaceuticals, acquired September 2023), country of origin USA, requested quantity (typically a 30-day or 90-day supply at 3 capsules daily), lot and expiry
- Destination dispensing facility license
- Chain-of-custody plan from the US specialty pharmacy (Biologics by McKesson is the sole exclusive US channel) through the importer to the receiving Saudi pharmacy
- Post-import pharmacovigilance commitment including hepatic and lipid monitoring schedule
Approval timelines for routine PIP applications at established Saudi institutions run 10 to 21 business days where the documentation is complete; first-time imports of a given product or applications from smaller dispensing facilities can extend to 4 to 8 weeks. Skyclarys is an oral small molecule with conventional 15 to 30 degree Celsius room-temperature storage and a long shelf life, so the cold-chain logistics that dominate biologic timelines do not apply.
Where Skyclarys gets dispensed in Saudi Arabia
The dispensing institutions that handle Skyclarys PIP cases as established workflow are the tertiary neurology centers in Riyadh, Jeddah, and the Eastern Province. King Faisal Specialist Hospital and Research Centre (KFSH&RC) Riyadh and Jeddah are the dominant institutional pathway given KFSH&RC's medical genetics service and movement disorders subspecialty depth; many Saudi FA diagnoses originate at KFSH&RC's genomics laboratory. King Abdulaziz Medical City (KAMC) within the Ministry of National Guard Health Affairs (MNGHA) network handles a meaningful neurology and pediatric neurology footprint with established PIP workflow. Prince Sultan Military Medical City (PSMMC) Riyadh and King Saud Medical City (KSMC) Riyadh participate where applicable.
On the private side, the major Saudi German Health, Dr. Sulaiman Al Habib Medical Group, and HMG (Habib Medical Group) flagship hospitals carry import pharmacy capacity, though FA-specific neurology subspecialty depth varies by site. The dispensing pharmacy must be SFDA-licensed, and the pharmacy in charge must hold an active SCFHS pharmacy license. For Skyclarys, the dispensing institution does not need cell or gene therapy capability; the standard institutional pharmacy infrastructure is sufficient because the product is an oral capsule.
Real cost picture for Skyclarys in Saudi Arabia
US WAC for Skyclarys is approximately USD 370,000 per year for the standard 150 mg daily oral dose (three 50 mg capsules once daily). Per-month WAC is approximately USD 30,800. At the SAR 3.75 peg, the annual range converts to approximately SAR 1.39 million per year (SAR 116,000 per month). The US specialty pharmacy channel is Biologics by McKesson under Biogen's exclusive distribution agreement; this is the sole authorised US channel and Reserve Meds sources directly through this channel under DSCSA chain-of-custody documentation.
International logistics for an oral small-molecule shipment to Saudi Arabia are modest relative to drug cost: typically USD 200 to USD 800 (approximately SAR 750 to SAR 3,000) per shipment depending on quantity and urgency. SFDA permit fees are nominal. The Reserve Meds concierge fee is itemised separately on every firm quote, and we typically build the order cadence around a 90-day supply to minimize repeat permit cycles while staying inside Skyclarys's shelf life.
On the payer side, Saudi insurer behavior for ultra-rare disease drugs at the USD 370,000-per-year price point is restrictive. Bupa Arabia, Tawuniya, and MedGulf assess case by case, with most commercial plans falling short of full coverage. Sovereign-tied institutional pathways (Royal Court Medical Care, Ministry of Health Higher Committee for Treatment Abroad) may apply for select cases. The Ministry of Health's Patient Treatment Abroad scheme is an additional channel for some patients. We do not promise coverage from any insurer or scheme. Cash-pay funded through family resources is the default operating posture for Reserve Meds-coordinated cases.
Typical timeline for Skyclarys in Saudi Arabia
SFDA PIP routine processing is typically 10 to 21 business days from a complete filing. Because Skyclarys is room-temperature stable, the international logistics layer is short: 3 to 5 days door-to-door for major Saudi metros, with customs clearance typically 1 to 3 business days where documentation is in order. End-to-end, most Saudi Skyclarys cases complete within 4 to 7 weeks from first complete documentation to first dispense. The titration phase, ramp from a lower starting dose to the full 150 mg daily over 7 days with hepatic function checks, is a clinical layer rather than a logistics layer, and the receiving institution paces that ramp.
What your physician needs to provide
For a Saudi-licensed adult neurologist, pediatric neurologist, or movement disorders specialist prescribing Skyclarys through the PIP, the clinical justification letter anchors the case. The letter, signed with active SCFHS registration, documents the FA diagnosis with biallelic GAA trinucleotide repeat expansion confirmed by a named genetics laboratory (specifying the GAA1 and GAA2 expansion sizes or the compound heterozygous mutation profile where applicable), the clinical phenotype with mFARS or equivalent scoring at baseline, age at onset, disease trajectory, the patient's age (confirmed 16 years or older), and the clinical rationale for Skyclarys as the first and only disease-modifying option.
The dosing plan follows the FDA label: titration from 50 mg daily for the first 2 days, 100 mg daily for the next 5 days, then 150 mg daily (three 50 mg capsules once daily) on an empty stomach. The monitoring plan covers baseline and ongoing ALT, AST, total bilirubin (with dose modification rules in the FDA label if hepatic transaminases exceed five times the upper limit of normal or bilirubin exceeds two times ULN), baseline and ongoing lipid panel (Skyclarys can increase LDL cholesterol), and clinical assessment of FA progression on a recurring schedule. The neurologist documents drug-interaction screening, particularly for moderate to strong CYP3A4 inducers (which reduce Skyclarys exposure) and inhibitors (which increase exposure).
The treating physician's SCFHS license number, the dispensing facility's SFDA license, and the pharmacy in charge of dispensing complete the package. Adverse event reporting through the SFDA National Pharmacovigilance Center applies and is referenced in the documentation kit; reporting obligations remain with the prescribing physician.
Common questions about Skyclarys in Saudi Arabia
Is Skyclarys registered with the SFDA? Not at this page date. Biogen has not filed Skyclarys for SFDA registration. Access for Saudi patients runs through the SFDA Personal Importation Program with US-source supply under the exclusive Biologics by McKesson channel.
My child is 14 years old with confirmed FA. Are they eligible? The FDA label is patients 16 years and older, and the FDA expanded the label down from 18 to 16 in September 2024. Skyclarys is not currently FDA-labeled for patients under 16. The treating neurologist makes the final eligibility call; for under-16 cases, off-label use would require a separate clinical justification and is not the standard PIP route.
Will Bupa Arabia, Tawuniya, or MedGulf cover the USD 370,000 annual cost? Saudi commercial insurers assess ultra-rare disease drugs case by case. Most commercial plans fall short of full annual coverage at this price point. Sovereign-tied institutional pathways and the Ministry of Health Patient Treatment Abroad scheme may apply for select cases. We do not promise coverage from any source. Cash-pay is the default operating posture.
What hepatic monitoring is required? The FDA label requires baseline ALT, AST, and total bilirubin, then monitoring at months 1, 2, and 3, and every 3 months thereafter. Dose modification rules apply if transaminases exceed five times ULN or bilirubin exceeds two times ULN. The receiving neurologist carries the monitoring schedule.
What about cardiac monitoring for FA-associated cardiomyopathy? Skyclarys itself does not require routine cardiac monitoring on the FDA label, but FA-associated hypertrophic cardiomyopathy is a structural feature of the disease and the treating neurologist typically pairs Skyclarys with a baseline echocardiogram and ongoing cardiology follow-up per individual case need. The Skyclarys file and the FA cardiology file run in parallel.
Can the medicine be shipped to my home address? No. SFDA PIP requires dispensing through an SFDA-licensed pharmacy. The institutional pharmacy releases the capsules to the patient or family after a clinical pickup; home delivery via the institution's outpatient pharmacy services is sometimes available depending on the institution's policy.
Are there other Friedreich's ataxia therapies in the pipeline I should know about? Several disease-modifying programs are in clinical development globally (gene therapy approaches targeting FXN, antisense oligonucleotides, additional small molecules). Skyclarys is the only FDA-approved disease-modifying therapy as of this page date. Patient advocacy organizations (Friedreich's Ataxia Research Alliance, Ataxia UK, MENA-region rare disease groups) maintain pipeline trackers. The treating neurologist is the right source for trial referral conversations.
Where Reserve Meds fits in Skyclarys cases
Reserve Meds is a US-based concierge coordinator. We do not replace your neurologist, we do not replace the SFDA, and we do not replace your dispensing pharmacy. For Skyclarys specifically, we orchestrate the US-side sourcing through the exclusive Biologics by McKesson specialty channel under DSCSA chain-of-custody, build the documentation kit your neurologist submits for the PIP application, coordinate room-temperature international logistics with documented hand-offs, assign a single named coordinator through the case, and stay through the multi-month titration and ongoing dosing arc including 90-day refill cadence. Genetic confirmation review is part of our intake to make sure the case fits the FA label before the PIP work begins.
Next step
If your neurologist has confirmed Friedreich's ataxia and you are weighing the cross-border Skyclarys route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.